New Brunswick, New Jersey 08903

  • Prostate Cancer

Purpose:

RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future. PURPOSE: This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer.


Study summary:

OBJECTIVES: - Determine bone mineral density (BMD) in patients with clinically significant early stage prostate cancer. - Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse (i.e., less than 3 years) than those patients with a low level of BMD. OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort study. Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry with a densitometer. Posteroanterior measurements of the total hip are also recorded. Patients also undergo blood collection to examine markers that provide evidence of systemic disease. Patients are followed every 6 months for 3 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Biopsy-confirmed early stage prostate cancer - Disease localized within the capsule - No evidence of regional or distant spread (i.e., T1-2, N0, M0 disease) - A cohort of patients must have undergone a prior radical prostatectomy - Prostate specific antigen < 12 ng/mL - Gleason score ≥ 6 PATIENT CHARACTERISTICS: - Creatinine clearance ≤ 2.0 mg/dL - No Paget's disease - No hyperthyroidism or hypothyroidism - No Cushing's disease - No chronic liver disease - No major health problems that would cause a significant reduction in mobility or activities of daily living PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior bisphosphonates, thyroxin, or calcitonin - No prior agents that suppress PSA levels (e.g., finasteride) - No prior androgen or estrogen therapy - More than 12 months since prior glucocorticoids - More than 12 months since prior herbal supplements that are known to lower PSA levels


NCT ID:

NCT00176579


Primary Contact:

Principal Investigator
Stephen W. Marcella, MD, MPH
Cancer Institute of New Jersey


Backup Contact:

N/A


Location Contact:

New Brunswick, New Jersey 08903
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.